# Safety And Tolerability Of Multiple Dose Lersivirine For 21 Days In Healthy Subjects

> **NCT01230385** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 75 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Lersivirine
- **DRUG:** Lersivirine
- **DRUG:** Lersivirine
- **DRUG:** Lersivirine
- **DRUG:** Lersivirine

## Key facts

- **NCT ID:** NCT01230385
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2011-05
- **Final completion:** 2011-05
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2011-05-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01230385

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01230385, "Safety And Tolerability Of Multiple Dose Lersivirine For 21 Days In Healthy Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01230385. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*